Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Deanne Mraz

Procedural Dermatology Westport, CT Medical Doctor

NPI 1659542397 CMS profile 257031

1032 Post Road East, Westport, CT 06880

Open in the dashboard

General payments

$249,698

448 records reported · program years 2019–2025

Research payments

$20,220

Paid to them · 17 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$2,060,708 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Deanne Mraz of Westport, CT is reported in the CMS Open Payments database as having received $249,698 across 448 general payments and $20,220 in research payments paid to them. Separately, studies naming them as principal investigator received $2,060,708 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 96th percentile of Procedural Dermatology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

12 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $10,360 21
2025 Research $896 7
2024 General $14,888 30
2024 Research $1,938 6
2023 General $11,137 64
2023 Research $5,220 1
2022 General $24,183 39
2022 Research $5,655 1
2021 General $33,517 47
2020 General $65,436 67
2019 General $90,179 180
2019 Research $6,512 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Deanne Mraz
  • Procedural Dermatology median
  • Middle half of Procedural Dermatology
  • National median

In program year 2025, general payments to Deanne Mraz were reported at $10,360. Among 381 Procedural Dermatology profiles paid that year, the median was $592 and the middle half received between $144 and $1,778.

Show as a table
Year Deanne Mraz Procedural Dermatology median Middle half National median
2019 $90,179 $454 $152–$1,260 $163
2020 $65,436 $243 $90–$835 $114
2021 $33,517 $337 $102–$1,128 $132
2022 $24,183 $443 $119–$1,654 $149
2023 $11,137 $583 $137–$1,838 $160
2024 $14,888 $611 $132–$1,835 $164
2025 $10,360 $592 $144–$1,778 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Merz North America, Inc. $73,106 78 payments
  2. Allergan Inc. $67,800 66 payments
  3. Endo Pharmaceuticals Inc. $48,691 44 payments
  4. Galderma Laboratories, L.P. $48,554 46 payments
  5. AbbVie, Inc. $6,984 24 payments
  6. Incyte Corporation $669 38 payments
  7. Avita Medical Americas, LLC $500 1 payment
  8. Aclaris Therapeutics, Inc. $500 1 payment
  9. Ortho Dermatologics, a division of Bausch Health US, LLC $397 22 payments
  10. Janssen Biotech, Inc. $348 15 payments
  11. Other $2,149 113 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $165,225 39 payments
  2. Travel and Lodging $37,178 63 payments
  3. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $35,065 10 payments
  4. Food and Beverage $12,140 334 payments
  5. Education $91 2 payments
Products named General payments · program years 2019–2025
  1. BOTOX COSMETIC $42,132 39 payments
  2. Xeomin $28,206 52 payments
  3. BOTOX $26,098 25 payments
  4. OPZELURA $669 38 payments
  5. RHOFADE $500 1 payment
  6. RECELL $500 1 payment
  7. SKYRIZI $309 15 payments
  8. TREMFYA $276 12 payments
  9. DUPIXENT $249 11 payments
  10. TALTZ $213 6 payments
  11. Other $2,948 152 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Merz North America, Inc. $10,875 2 payments
  2. Endo Pharmaceuticals Inc. $6,512 2 payments
  3. AbbVie, Inc. $2,833 13 payments

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

18

Median for Dermatology: 534

Drug cost

$317

Median for Dermatology: $67,151

Branded share of claims

0%

Median for Dermatology: 8.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ketoconazole Generic 18 $317

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 13,550 Part D prescribers listed as Dermatology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 31 billing codes

Paid by Medicare

$26,588

Of which drugs: $1,078

Medicare patients

101

Average age 74

Services billed

1,341

83 women, 18 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 49%
High blood pressure 47%
Osteoporosis 33%
Ischemic heart disease 20%
Cancer 19%
Diabetes 16%
Chronic kidney disease 12%
Depression 11%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
OPZELURA
  • Incyte Corporation $283
$283 — —
TREMFYA
  • Janssen Biotech, Inc. $71
$71 — —
RINVOQ
  • AbbVie, Inc. $23
$23 — —
SKYRIZI
  • AbbVie, Inc. $21
$21 — —
Otezla
  • Amgen Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

465 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Procedural Dermatology in Connecticut

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record